In view of the array of symptoms, the patient was referred for medical evaluation of a suspected pheochromocytoma, a neuroendocrine tumor of the adrenal gland. He underwent 24-hour blood pressure ...

The role of chromogranin A in the assessment of surgical cure of pheochromocytoma was also investigated. The authors observed 21 consecutive patients who had pheochromocytomas at initial ...

As outlined by patient representatives at the ISP ... remains recommended for all cases of pheochromocytoma or paraganglioma.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Patients with MEN-1 may develop tumors in the pancreas, which then release excess hormones. MEN type 2A can cause medullary thyroid cancer, hyperparathyroidism, and pheochromocytoma. MEN type 2B is a ...

“Pheochromocytoma and paraganglioma are rare tumors that form in and around the adrenal glands, and currently, there are no approved therapies available in the U.S. for patients with this rare disease ...

First, because of periodic surveillance of patients with a hereditary predisposition ... have become an important clinical entity for which pheochromocytoma must be considered, regardless of ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.